

Reinstatement to Trading Update

Advanced Health Intelligence Ltd (ASX/NASDAQ:AHI) (**AHI** or the **Company**) wishes to provide its shareholders with an update with respect to the Company's ongoing communications with ASX to have its securities reinstated to trading on the official list of the Australian Securities Exchange (**ASX**).

As announced on 19 June 2024, the Company had received guidelines from ASX stating that the Company's securities will be reinstated to trading on the ASX, subject to the satisfaction of certain conditions precedent.

The conditions precedent required to be satisfied by the Company before its securities are reinstated to official quotation on the ASX are:

- The Company securing AUD\$4 million in cleared funds in the Company's Bank account, to the satisfaction of the ASX; and
- AHI confirming the above in an ASX announcement and releasing any required ASX forms (including Appendix 3Bs for any proposed security issues).

The conditional reinstatement of the Company's securities to trading on the ASX is subject to the following caveats:

- Upon satisfaction of the previous two bullet points, ASX intends to reinstate AHI's securities to official quotation; and
- The ASX has the discretion not to reinstate AHI's securities to official quotation should the Company fail to comply with the Listing Rules, the spirit of the Listing Rules, or if other information comes to light.

In the most recent communication from the ASX, it has advised that it will review the Company's audited financial statements for the year ending 30 June 2024, and will provide further queries once they have been reviewed.

AHI is continuing to work with ASX to ensure the satisfaction of all compliance requirements as quickly as possible, and will provide shareholders with a further update regarding developments as the Company works towards the reinstatement of its securities to official quotation on the ASX.

The Company expects to have a further update for shareholders following the release of its annual financial accounts which are due for release on or before 30 September 2024.

The Chairman and CEO of Advanced Health Intelligence Ltd have approved this announcement.

For more information, contact:

Scott Montgomery
Chief Executive Officer
Advanced Health Intelligence Ltd
E: admin@ahi.tech

Simon Durack
Company Secretary & Chief Financial Officer
Advanced Health Intelligence Ltd
E: admin@ahi.tech

About Advanced Health Intelligence Ltd

AHI delivers scalable health assessment, risk stratification and digital triage capabilities to healthcare providers, insurers, employers, and government agencies worldwide via our proprietary technology and processes.

ASX/NASDAQ Announcement 23 September 2024



Since 2014, AHI has been delivering Health-tech innovation via a smartphone, starting with the world's first ondevice body dimensioning capability. AHI has developed a patented technology, showcasing the next frontier in digitising healthcare with a suite of componentised solutions, culminating in:

- Body dimension and composition assessment to identify the comorbidities of obesity, such as diabetes risk estimates.
- Blood biomarker estimation, including HbA1C, HDL, LDL, and 10-year mortality risk.
- Transdermal Optical Imaging is used to return vital signs and provide risk estimates for cardiovascular disease.
- On-device dermatological skin identification across 588 skin conditions across 133 categories (Inc. Melanoma); and
- Assisting partners in delivering personalised therapeutic and non-therapeutic health coaching to improve daily habits and build health literacy.

Our world-class team of subject matter experts in machine learning, AI, computer vision, and medically trained data scientists ensure that AHI's technology is at the forefront of innovation and the needs of our consumers. With a focus on impact at scale, AHI is proud to showcase this milestone in digital healthcare transformation, delivering a biometrically derived triage solution accessible on and via a smartphone. With these advanced technologies, AHI helps its partners identify risks across their consumers and triage them into right-care pathways for proactive health management at a population scale.

For more information, please visit: www.ahi.tech